Fresh Equities
Offers
Learn
KAZIA THERAPEUTICS LIMITED

INVESTOR PRESENTATION - KAZIA THERAPEUTICS LIMITED

ASX:KZA

KAZIA THERAPEUTICS LIMITED

Health Care

Kazia Therapeutics Limited Is an oncology-focused biotechnology company. KZA is focused on the development of novel anti-cancer drugs based on two proprietary drug technologies known as Super-benzopyrans and Anti-tropomyosins. KZA is headquartered in Sydney, Australia, with an office in New Haven, Connecticut in the US.

Read more

Market Cap

91.78m

Price at Close

$0.97

4w avg. Volume

282.56k

4w avg. Turnover

$288.62k

Announcements
announcementt+2 movementdate
  • Kazia AGM and closing date for director nominations

    Notice Of Meeting

  • -

    18 Sep 2020

-

18 Sep 2020
  • Kazia presents to H C Wainwright conference

    Periodic Reports

  • -2.53%

    15 Sep 2020

-2.53%

15 Sep 2020
  • Conversion of options

    Issued Capital

  • -1.37%

    31 Aug 2020

-1.37%

31 Aug 2020
  • Kazia change in directors interests

    Shareholder Details

  • -1.37%

    31 Aug 2020

-1.37%

31 Aug 2020
  • Kazia change in directors interests

    Shareholder Details

  • +8.91%

    28 Aug 2020

+8.91%

28 Aug 2020
  • Kazia Appendix 4E

    Periodic Reports · Market sensitive

  • +2.02%

    26 Aug 2020

+2.02%

26 Aug 2020
  • Kazia Annual Report to shareholders

    Periodic Reports

  • +2.02%

    26 Aug 2020

+2.02%

26 Aug 2020
  • Kazia Corporate Governance Statement

    Periodic Reports

  • +2.02%

    26 Aug 2020

+2.02%

26 Aug 2020
  • Kazia Appendix 4G

    Periodic Reports

  • +2.02%

    26 Aug 2020

+2.02%

26 Aug 2020
  • Change in substantial holding

    Shareholder Details

  • +3.00%

    25 Aug 2020

+3.00%

25 Aug 2020
Market Data

Current Price

$0.97

52WK HIGH

$1.235

52WK LOW

$0.37

1YR RETURN

+92.08%

1YR RETURN VS. SECTOR

+61.90%

90 DAY RETURN

+106.38%

ASX RANK

809

/2,019

SECTOR RANK

16

/47

SHARES OUTSTANDING

94.62m
ASX:KZA

KAZIA THERAPEUTICS LIMITED

Health Care

Kazia Therapeutics Limited Is an oncology-focused biotechnology company. KZA is focused on the development of novel anti-cancer drugs based on two proprietary drug technologies known as Super-benzopyrans and Anti-tropomyosins. KZA is headquartered in Sydney, Australia, with an office in New Haven, Connecticut in the US.

Read more

Market Cap

91.78m

Price at Close

$0.97

4w avg. Volume

282.56k

4w avg. Turnover

$288.62k

ASX:KZA is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Support

Live Chat

Research
Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.